The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genzyme; HERON; Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Genzyme; Regeneron
Research Funding - Imugene (Inst); Novartis (Inst); Regeneron (Inst)
IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of imu-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101).
 
Gary Edward Richardson
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Merck (Inst); Novotech (Inst); Pfizer (Inst); Roche/Genentech (Inst); Shanghai Henlius Biotech (Inst); Suzhou Alphamab (Inst); Takeda (Inst)
 
John J. Park
Research Funding - Imugene (Inst)
 
Michael J. Boyer
Honoraria - AstraZeneca; CancerAid
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Amgen (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Imugene (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst)
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Speakers' Bureau - BMS; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb Japan; Daiichi Sankyo; Eisai; EMD Serono; Flame Biosciences; Genentech/Roche; Geneplus; GlaxoSmithKline; Gritstone Bio; Intellisphere; Janssen; Johnson & Johnson/Janssen; Lilly; Merck; Mirati Therapeutics; Novocure; OncoCyte; Oncohost; Regeneron; Roche China; Sanofi; Seagen
Research Funding - Bristol-Myers Squibb
 
Panayiotis Savvides
No Relationships to Disclose
 
Pravin Kaumaya
Consulting or Advisory Role - Imugene
Research Funding - Imugene (Inst)
Patents, Royalties, Other Intellectual Property - Imugene; Imugene (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Tri Guang Phan
Consulting or Advisory Role - Imugene
 
Leslie Mi Ok Chong
Employment - Imugene
Leadership - Chimeric Therapeutics; Imugene
Stock and Other Ownership Interests - Chimeric Therapeutics; Chimeric Therapeutics (I); Imugene; Imugene (I)
Patents, Royalties, Other Intellectual Property - Imugene (Inst)
 
Steven Cha
Employment - Imugene; NKGen Biotech; Samumed
Leadership - Imugene; NKGen Biotech; Samumed
Stock and Other Ownership Interests - Imugene; NKGen Biotech; Samumed
Patents, Royalties, Other Intellectual Property - Imugene (Inst)
 
Nicholas Ede
Employment - Imugene
Leadership - Imugene
Stock and Other Ownership Interests - Imugene
Patents, Royalties, Other Intellectual Property - Imugene; Imugene (Inst)
 
Bonnie Nixon
Employment - Imugene
Stock and Other Ownership Interests - Chimeric Therapeutics; Chimeric Therapeutics (I); Imugene; Imugene (I)
Patents, Royalties, Other Intellectual Property - Imugene (Inst)
 
Anthony J Good
Employment - Imugene
Stock and Other Ownership Interests - Chimeric Therapeutics; Imugene
Patents, Royalties, Other Intellectual Property - Imugene (Inst)